Article

Hormone Replacement Therapy Increases Gallbladder Disease Risk

Scientists from the University of Oxford have found that hormone replacement therapy in post-menopausal women increases the risk of gallbladder disease.

Scientists from the University of Oxford have found that hormone replacement therapy (HRT) in post-menopausal women increases the risk of gallbladder disease. They analyzed data from the Million Women Study, which involved 1,001,391 post-menopausal women from the UK with an average age of 56. The women were followed for an average of six years. During this time, 19,889 women were admitted to a hospital with gallbladder disease, 17,190 (86%) of whom underwent cholecystectomy (surgical removal of the gallbladder).

The higher the dosage of HRT, the higher the risk was. Once the therapy was discontinued, the risk decreased over time. Results also showed that there was a lower risk if the HRT was administered through skin patches, or as a gel; the risk increased if the HRT was administered orally. This may be because orally administered HRT is metabolized by the liver before it enters the rest of the system.

“Standardised hospital admission rates per 100 women over five years for cholecystectomy were 1.1 in never users, 1.3 with transdermal therapy, and 2.0 with oral therapy,” the researchers stated. “Use of transdermal therapy rather than oral therapy over a five year period could avoid one cholecystectomy in every 140 users.”

The full research findings were published in the British Medical Journal and can be found here.

Related Videos
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data | Image Credit: HCPLive
Diabetes Dialogue: Latest Updates on Semaglutide Shortage, Data | Image Credit: HCPLive
Richard Pratley, MD | Credit: Advent Health Diabetes Institute
Rahul Aggarwal, MD | Credit: LinkedIn
Brendon Neuen, MBBS, PhD | Credit: X.com
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Ralph DeFronzo, MD | Credit: UT San Antonio
Timothy Garvey, MD | Credit: University of Alabama at Birmingham
Atul Malhotra, MD | Credit: Kyle Dykes; UC San Diego Health
Optimizing Diabetes Therapies with New Classifications
© 2024 MJH Life Sciences

All rights reserved.